Intrexon Corp (XON) 56.77 $XON
Fibrocell Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jul 21, 3:01PM CDT
Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, today announced that it has commenced an underwritten public offering of its common stock pursuant to its existing shelf registration statement. All of the shares in the offering are to be sold by Fibrocell.
FCSC: 5.85 (+0.19), XON: 56.77 (-1.18)
Intrexon Augments Management Team
PR Newswire - Tue Jul 21, 7:00AM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced three additions to the executive team -- Jack A. Bobo, as Senior Vice President, Chief Communications Officer, Samuel Broder, M.D., as Senior Vice President, Head of Health Sector, and Joel Liffmann as Senior Vice President, Finance.
XON: 56.77 (-1.18)
Fibrocell Science and Intrexon partnership submits IND Application to the US FDA for FCX-007 for treating recessive dystrophic epidermolysis bullosa
M2 - Tue Jul 21, 5:06AM CDT
Gene therapy company Fibrocell Science (NasdaqCM:FCSC) disclosed on Monday the submission of an Investigational New Drug (IND) Application with the US Food and Drug Administration for its lead orphan gene-therapy drug candidate FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) in partnership with
Fibrocell Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jul 21, 3:01PM CDT
Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, today announced that it has commenced an underwritten public offering of its common stock pursuant to its existing shelf registration statement. All of the shares in the offering are to be sold by Fibrocell.
FCSC: 5.85 (+0.19), XON: 56.77 (-1.18)
Intrexon Augments Management Team
PR Newswire - Tue Jul 21, 7:00AM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced three additions to the executive team -- Jack A. Bobo, as Senior Vice President, Chief Communications Officer, Samuel Broder, M.D., as Senior Vice President, Head of Health Sector, and Joel Liffmann as Senior Vice President, Finance.
XON: 56.77 (-1.18)
Fibrocell Science and Intrexon partnership submits IND Application to the US FDA for FCX-007 for treating recessive dystrophic epidermolysis bullosa
M2 - Tue Jul 21, 5:06AM CDT
Gene therapy company Fibrocell Science (NasdaqCM:FCSC) disclosed on Monday the submission of an Investigational New Drug (IND) Application with the US Food and Drug Administration for its lead orphan gene-therapy drug candidate FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) in partnership with
